Regional clustering of shared neutralization determinants on primary isolates of Clade C human immunodeficiency virus type 1 from South Africa

Journal of Virology

Volumn 76, Issue 5, 2002, Pages 2233-2244

  Bures, Renata ^a   Morris, Lynn ^a   Williamson, Carolyn ^a   Ramjee, Gita ^a   Deers, Mark ^a   Fiscus, Susan A ^a   Abdool Karim, Salim ^a   Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; REAGENT;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALAWI; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; PROSTITUTION; SEROTYPE; SOUTH AFRICA; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PROSTITUTION; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA;

EID: 0036170703     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.76.5.2233-2244.2002     Document Type: Article

References (87)

1. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
2. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
3. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies
4. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
5. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
6. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors
7. Identification of HIV-1 inter-subtype recombinants in South Africa using env and gag heteroduplex mobility assays
8. Genetic characterization of HIV type 1 from migrant workers in three South African gold mines
9. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
10. The antibody response in HIV-1 infection
11. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
12. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type I clades: Implications for vaccine development
13. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
14. + T-cell counts and T-cell function in long-term AIDS-free infection
15. Detection of HIV type 1 env ubtypes A, B, C, and E in Asia using dried blood spots: A new surveillance tool for molecular epidemiology
16. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India
17. Core structure of gp41 from the HIV envelope glycoprotein
18. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
19. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
20. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
21. Identification of a major co-receptor for primary isolates of HIV-1
22. + cells is mediated by the chemokine receptor CC-CKR-5
23. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
24. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein
25. Variation in HIV type 1 V3 region env sequences from Mozambique
26. HIV type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal, and Western Cape Provinces of South Africa
27. Accelerating the development and future availability of HIV-1 vaccines: Why, when, where and how?
28. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G proteincoupled receptor
29. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
30. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity
31. Transmission of genetically diverse strains of HIV-1 in Puna, India
32. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin
33. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity
34. Serologic responses to candidate AIDS vaccines
35. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
36. The recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates
37. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement
38. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1
39. Delineation of a region of the human immunodeficiency virus gp120 glycoprotein critical for interaction with the CD4 receptor
40. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination
41. Gender differences in HIV-1 diversity at the time of infection
42. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
43. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
44. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay
45. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
46. Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype
47. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
48. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
49. HIV genetic diversity
50. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
51. Toward an HIV-1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
52. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
53. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
54. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
55. Interand intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
56. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis
57. Human trials of HIV-1 vaccines
58. A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1
59. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: A set of 23 full-length clones from Botswana
60. Multivariate analysis of human immunodeficiency virus type 1 neutralization data
61. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
62. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term non-progressive infection
63. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants
64. Antibody neutralization of HIV-1
65. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
66. Prevalence of sexually transmitted infections among sex workers in the Kwazulu-Natal midlands, South Africa
67. A role for carbohydrates in immune evasion in AIDS
68. HIV-1 nomenclature proposal - A reference guide to HIV-1 classification
69. Gene regulating HLA class I antigen expression in T-B lymphoblast hybrids
70. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
71. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer
72. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
73. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
74. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
75. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
76. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
77. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers
78. An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa
79. Characterization of the full-length HIV type 1 subtype C sequences from South Africa
80. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations
81. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype
82. Atomic structure of the ectodomain from HIV-1 gp41
83. CD4-induced interaction or primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
84. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
85. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B
86. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells